MedTrace Logo

Effects of Rosiglitazone on Plasma BNP Levels and Left Ventricular Dysfunction

NCT00300911 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2006-03-10

No results posted yet for this study

Summary

The present study aimed to evaluate the effect of rosiglitazone treatment on cardiac function compared with metformin

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Rosiglitazone(drug), cardiac adverse effects

Sponsors & Collaborators

  • Baskent University

    lead OTHER

Principal Investigators

  • Yasemin T Kemal, MD · Medical Doctor, Internal Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00300911 on ClinicalTrials.gov